- 1. PSA Prostate Cancer Vaccine
- [A peptide vaccine containing the prostate specific antigen (PSA) with potential antineoplastic activity. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marked for both diagnosis and treatment evaluation. Vaccination with PSA peptide vaccine may produce anti-PSA antibodies as well as elicit a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby, decreasing tumor cell growth. ( NCI )] (UMLS (NCI) C0796406) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 3. psammoma bodies
- [(sam-O-ma) Structures found in some benign (noncancerous) or malignant (cancerous) tumor cells that look like hardened concentric rings when viewed under a microscope. Can be a sign of chronic inflammation. ( NCI )] (UMLS (NCI) C0391863) =Body Substance ;
|
- 2. PSA RNA-Pulsed Dendritic Cell Vaccine
- [An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to prostate cancer patients, these RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive tumor cells, thereby, decreasing tumor cell growth. ( NCI )] (UMLS (NCI) C0879395) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 4. Psammomatous Meningioma
- [A WHO grade I meningioma showing many psammoma bodies that may become confluent, forming irregular calcified and occasionally, ossified masses. These tumors often occur in the thoracic spinal region, usually in middle-aged women. (Adapted from WHO 2000.) ( NCI )] (UMLS (NCI) C0334607) =Neoplastic Process
|
home
